Latest News

If you are looking for the next move on Cirrus Logic (CRUS), this week’s news may have caught your eye. The company just expanded its collaboration with GlobalFoundries, aiming to bring highly efficient and powerful chip technologies to market—from consumer gadgets to cars. This partnership goes beyond a routine announcement, as it promises fresh manufacturing capacity in the U.S. along with advances in critical chip technologies such as BCD process and Gallium Nitride, which could shape...

Mercury General (MCY) has been gaining attention after being tagged as a “Strong Buy” by Zacks and called out for its attractive value metrics compared to competitors. This spotlight arrives on the heels of several positive catalysts, including a rise in net premiums, better investment income, and an updated umbrella insurance product newly launched in Florida. These factors have fueled talk about MCY's underlying business strength and whether the recent run-up is a sign of deeper,...

Axsome Therapeutics (AXSM) just dropped some news that should have every shareholder paying attention. Apotex has officially filed an ANDA with the FDA, complete with a Paragraph IV certification, aiming to launch a generic version of Symbravo. This move signals the possibility of a legal battle over patents, which could determine how long Symbravo remains protected from generic competition. For investors, that means the stakes are high. Any change in exclusivity could reshape revenue streams...

With the business potentially at an important milestone, we thought we'd take a closer look at Axogen, Inc.'s...

Powell Industries (POWL) just made a splash, announcing a $12.4 million expansion at its Jacintoport manufacturing facility in Houston. With this move, the company is increasing production capacity by 62% and doubling the shoreline bulkhead, both clear signals that management sees bigger business on the horizon. While this fresh capital is aimed primarily at serving Oil & Gas clients, there is flexibility built in for other markets as well. For investors, anytime a company puts serious money...

British American Tobacco (LSE:BATS) recently caught investors’ attention following a steady climb in the share price, even though there has been no headline-grabbing event to explain the move. Sometimes the market makes subtle shifts that do not get much coverage, but investors may want to pay attention to these signals. If you have been watching BATS and wondering whether this momentum is the start of something bigger or just another routine swing, you are not alone. This uptick builds on a...

SelectQuote ( NYSE:SLQT ) Full Year 2025 Results Key Financial Results Revenue: US$1.53b (up 16% from FY 2024). Net...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Hovnanian Enterprises ( NYSE:HOV ) Third Quarter 2025 Results Key Financial Results Revenue: US$800.6m (up 11% from 3Q...

Hamilton Beach Brands Holding Company's ( NYSE:HBB ) price-to-earnings (or "P/E") ratio of 6.3x might make it look like...

The board of Insteel Industries, Inc. ( NYSE:IIIN ) has announced that it will pay a dividend of $0.03 per share on the...

Key Insights Institutions' substantial holdings in Allient implies that they have significant influence over the...

TrustCo Bank Corp NY's ( NASDAQ:TRST ) periodic dividend will be increasing on the 1st of October to $0.38, with...

JB Hi-Fi Limited recently announced full-year results for June 2025 with sales reaching A$10.55 billion and net income rising to A$462.4 million, alongside a special dividend of A$1.00 per share and an increase in its dividend payout ratio for the next fiscal year. An important insight is that the company's free cash flow outpaced its statutory profit, pointing to robust underlying earnings and strong cash generation. We'll examine how the higher dividend payout guidance and cash flow...

Earlier this month, Marriott International completed a multi-part fixed-income offering totaling over US$1.4 billion, issuing callable senior unsecured notes with fixed rates and due dates ranging to October 2035, and expanded its banking partnerships to include institutions such as Wells Fargo, PNC, Scotia, Truist, and others. This transaction not only enhances Marriott's liquidity and financial flexibility but also underscores strong investor and institutional confidence in the company's...

Virtus Investment Partners recently announced that its Board of Directors approved a 7% increase in its quarterly common stock cash dividend, raising it from US$2.25 to US$2.40 per share, payable on November 14, 2025 to shareholders of record as of October 31, 2025. This move highlights the company's focus on returning capital to shareholders and reflects management’s confidence in the firm’s ongoing performance. We’ll now explore how this dividend increase strengthens Virtus Investment...

On August 19, 2025, Breville Group announced a fully franked interim dividend of A$0.19 per security for the six months ended June 30, 2025, alongside its full-year financial results showing sales rose to A$1.70 billion and net income reached A$135.85 million. As part of its recent update, Breville Group highlighted both strong earnings growth and ongoing strategic steps to offset input cost pressures, including manufacturing diversification and geographic expansion. We'll now explore how...

Hudbay Minerals (TSX:HBM) just posted second-quarter earnings that made some investors do a double take. Sales surged to $536 million from $425 million last year, and a net loss has swung dramatically to a $118 million profit. Not only did earnings per share turn positive, but Hudbay also underscored its confidence by reaffirming full-year production guidance for both copper and gold, two metals at the heart of its story. The market seems to be digesting a company that is firing on more...

H&R Real Estate Investment Trust recently reported its second quarter and first half 2025 results, with sales of C$204.01 million and a net loss of C$166.37 million for the second quarter, and affirmed a monthly dividend of C$0.05 per share. The reduction in net loss compared to the previous year, despite a slight dip in sales, highlights the company's ongoing efforts to manage its financial performance. We’ll examine how the combination of affirmed dividends and narrowing losses shapes H&R...

If you are watching LegalZoom.com (LZ) right now, you might be wondering what today's launch of attorney-assisted provisional patent application services could mean for your investment decision. By moving deeper into intellectual property legal services, LegalZoom is signaling it wants a larger slice of the innovation economy, one that has long been out of reach for many startups and solo inventors. This new offering addresses classic hurdles in patent protection, promising inventors a...

Here’s something for GE Vernova (NYSE:GEV) watchers to note. After a mixed run through spring and early summer, the company’s stock just closed at $607.07, reflecting virtually no movement on the day. While there is no major headline event driving the action, the relative calm might have investors wondering if the current price holds hidden signals about what could be next for the power and energy infrastructure company. Put in context, GE Vernova’s journey in the past year has been anything...

RTX (RTX) grabbed headlines this week after a relatively flat session, with the stock closing at $156.24, down just slightly from the previous day. It is not a splashy move, but it raises the question for investors: Are we simply seeing a pause, or is this a signal that the market is growing more cautious after a year of strong gains? In a year marked by both broader market optimism and persistent macro uncertainty, even minor movements in big names like RTX tend to get noticed. Looking at...

LightPath Technologies, Inc. ( NASDAQ:LPTH ) shares have continued their recent momentum with a 26% gain in the last...

If you have been tracking Ultragenyx Pharmaceutical (RARE), the latest regulatory move may have caught your eye. The company just kicked off a rolling submission for its Biologics License Application to the FDA, targeting approval for DTX401, an AAV gene therapy designed for Glycogen Storage Disease Type Ia. This step is backed by data from its Phase 3 trial, with encouraging reductions in patient daily cornstarch needs. It is also supported by several FDA designations that signal a real...